Clinical Trial Update: A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of ALTA2618 for AKT1 E17K-mutant solid tumors is currently recruiting, with breast cancer and endometrial cancer among the indicated conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Endometrial Cancer
• Solid Tumors

Drugs mentioned

• ALTA2618

Snippet

Sponsor: Alterome Therapeutics, Inc. | Conditions: Cancer, Breast Cancer | Phase 1 | Status: RECRUITING